Fintech

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

Globenewswire·April 20, 2026 at 11:01 AM

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)...

Original Source

Globenewswire — www.globenewswire.com

Related in Fintech

Amazon, Anthropic Deepen AI Partnership
PYMNTS
Commercial Loans Show US Economy Defies Forecasts
PYMNTS
Zenskar Raises $15 Million for Agentic AI
PYMNTS
Apple Hardware Leader John Ternus to Succeed CEO
PYMNTS

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

Amazon, Anthropic Deepen AI Partnership

Commercial Loans Show US Economy Defies Forecasts

Zenskar Raises $15 Million for Agentic AI

Apple Hardware Leader John Ternus to Succeed CEO